Key Highlights
- Eli Lilly announces $3 billion investment in China spanning the next ten years
- Funding targets orforglipron production, the company’s oral GLP-1 medication for weight management
- Marketing application for orforglipron submitted to Chinese regulators in late 2025
- Bernstein maintains Outperform rating at $1,300 price target; shares currently near $1,008
- LillyConnect platform debuts, enabling employers to tailor GLP-1 benefits through partnerships with GoodRx and Cost Plus Drugs
Eli Lilly ($LLY) revealed Wednesday a commitment to deploy $3 billion across China throughout the coming decade. The pharmaceutical giant plans to use these funds to establish manufacturing infrastructure for orforglipron, a once-daily oral medication designed to address type-2 diabetes and weight management.
The drugmaker shared the news via WeChat, revealing that it has already filed a marketing application for orforglipron with Chinese regulatory authorities at the close of 2025. Regulators are now reviewing that submission.
Orforglipron represents a non-peptide GLP-1 agonist — a different mechanism than Lilly’s current injectable options like Zepbound. Clinical trial results from late-stage testing showed participants who were overweight and without diabetes achieved an average 12.4% body weight reduction over 72 weeks when taking the maximum dose.
Additional research demonstrated that orforglipron supports sustained weight management when patients transition from Zepbound or Novo Nordisk’s Wegovy. This finding strengthens Lilly’s position as it develops the oral GLP-1 segment.
The China investment includes plans to establish domestic manufacturing and distribution infrastructure for oral solid dosage medications. This approach would decrease dependence on imported products and improve regional supply chain efficiency.
The move aligns Lilly with other Western healthcare companies expanding operations in China, such as Haleon and AstraZeneca, which made comparable announcements earlier this year.
The announcement arrives ahead of a scheduled summit between U.S. President Donald Trump and China’s Xi Jinping later this month.
Meanwhile, some pharmaceutical companies are taking a different approach. Bristol-Myers Squibb announced in September plans to divest its 60% ownership in a Chinese pharmaceutical partnership, which includes a Shanghai production facility.
Bernstein Maintains $1,300 Price Objective
Bernstein SocGen reaffirmed its Outperform rating alongside a $1,300 price objective for LLY stock this week, following recent developments regarding GLP-1 distribution channels in the United States. Shares currently trade near $1,008.
The research firm emphasized CMS guidance on the BALANCE model, establishing a $245 Medicaid price floor for obesity medications beginning May 2026, with Medicare coverage expanding in July 2026. The complete initiative operates from January 2027 through 2031 — reaching beyond the current administration’s term.
Bernstein stated the extended timeframe delivers price stability for Lilly through semaglutide’s patent expiration in 2031.
LillyConnect Platform and Prescription Trends
Lilly introduced LillyConnect last week, a platform enabling employers to establish dedicated GLP-1 insurance benefits for their workforce. The company has secured partnerships with 15 program administrators, including GoodRx and Mark Cuban’s Cost Plus Drugs, along with two pharmacy partners: CentreWell and HealthDyne.
The system provides employers with customization options for coverage parameters and cost-sharing arrangements, potentially reducing out-of-pocket expenses versus direct cash payment.
Morgan Stanley, maintaining an Overweight rating with a $1,313 objective, viewed the platform introduction favorably. Deutsche Bank continues with a Buy rating at a $1,285 target.
Prescription data shows Mounjaro recorded approximately 724,500 total prescriptions during the week ending February 27, representing growth from the previous week. Deutsche Bank observed a 7% week-over-week increase in overall GLP-1 prescription volume.
Morgan Stanley highlighted that supply limitations had constrained Mounjaro sales in Brazil, though a significant uptick in February imports suggests availability is recovering.
